Skip to main content

Table 1 Baseline characteristics of the study populations

From: Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project

 

Population-based cohorts

Disease cohorts

Number of cohorts, n

20

3

Number of subjects, n

75,367

4982

Men, n (%)

38,350 (50.9%)

3766 (75.6%)

Age at baseline, years

 Median (Q1, Q3)

50.0 (41.0, 59.0)

63.0 (54.0, 69.0)

 Proportion ≥ 65 years

13.1%

42.6%

Daily smokers, n (%)

24,077 (31.9%)

892 (17.9%)

Diabetes, n (%)

3286 (4.4%)

930 (18.7%)

Hypertension, n (%)

30,811 (40.9%)

3514 (70.5%)

Body mass index (kg/m2), mean (SD)

26.9 (4.6)

27.6 (4.1)

Total cholesterol (mmol/L)*

5.7 (5.0, 6.5)

4.9 (4.1, 5.7)

CRP (mg/L)*

1.3 (0.6, 2.9)

1.5 (0.4, 5.1)

Nt-proBNP (pg/mL)*

45.9 (24.2, 86.3)

308.0 (116.0, 803.0)

Troponin I (ng/L)*

2.3 (1.4, 3.7)

10.4 (4.6, 29.7)

eGFR (mL/min/1.73m2)*

 CKD-EPIcrea

97.6 (85.9, 107.6)

82.7 (68.7, 94.6)

 CKD-EPIcysC

92.5 (76.4, 111.5)

91.1 (69.1, 116.2)

CKD stage 3+, n (%)

 CKD-EPIcrea

2450 (3.3%)

691 (13.9%)

 CKD-EPIcysC

5562 (7.4%)

719 (14.4%)

Endpoints (n, incidence rate per 1000 person years (95% CI))

 Cardiovascular disease

6850, 8.2 (95% CI 8.0–8.4)

371, 21.2 (95% CI 19.2–23.5)

 Cardiovascular mortality

3796, 4.2 (95% CI 4.1–4.3)

132, 6.9 (95% CI 5.8–8.2)

 Total mortality

9840, 10.9 (95% CI 10.6–11.1)

343, 17.9 (95% CI 16.1–19.9)

  1. *Median (interquartile range, Q1, Q3)